<DOC>
	<DOC>NCT00970385</DOC>
	<brief_summary>This is a multicenter randomized trial evaluating induction treatment with VIP-reinforced-ABVD (VIP-rABVD) versus CHOP/21 in patients with newly diagnosed peripheral T cell lymphoma.</brief_summary>
	<brief_title>Study About Treatment of Newly Diagnosed Non Cutaneous Peripheral T Cell Lymphoma</brief_title>
	<detailed_description>Induction therapy: ARM 1: 6 Chemotherapy courses = 3 VIP alternated with 3 ABVD ARM 2: 8 Chemotherapy courses = CHOP every 21 days Consolidation therapy: For all patients if CR = radiotherapy 40GY / 5X1,8 GY per week</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, T-Cell</mesh_term>
	<mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>newly diagnosed untreated PTCL age 18 and 70 years performance status â‰¤ 2 Ann Arbor stage I to IV normal cardiac ventricular ejection fraction over 50% normal hepatic function (asat, ALAT, PAL &lt; 2.5 ULN) cutaneous form of PTCL previous treatment age &lt; 18 and &gt; 70 performance status &gt; 2 abnormal cardiac or hepatic functions HIV, HCV or HBV positivity</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2009</verification_date>
</DOC>